EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort

Yoshiyuki Yokomaku iD, Katsuji Teruya, Dai Watanabe, Tomoyuki Endo, Rumi Minami, Nao Taguchi, Tali Cassidy, Andrea Marongiu, David Thorpe, Takuma Shirasaka iD, Shinichi Oka

PLOS ONE · 08.01.2025 · 20 (1) · e0313338

DOI: 10.1371/journal.pone.0313338 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PLOS ONE, online erschienen am 08.01.2025. Verfasst von Yoshiyuki Yokomaku und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan. Hauptthemen laut MEDLINE: HIV Infections, Emtricitabine, Tenofovir, Anti-HIV Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BICSTaR (BICtegravir Single Tablet Regimen) is an ongoing, observational cohort study assessing the virologic effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-experienced (TE) and treatment-naïve (TN) people with HIV across 14 countries over 24 months. We present 12-month outcomes from participants in the BICSTaR Japan cohort. Retrospective and prospective data were pooled from people with HIV aged ≥20 years receiving B/F/TAF within routine clinical care in Japan. Outcomes included virologic effectiveness (primary endpoint; HIV-1 RNA

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsEmtricitabineTenofovirAnti-HIV AgentsAlanineHeterocyclic Compounds, 3-RingPyridonesHeterocyclic Compounds, 4 or More RingsHumansMaleAdultFemaleJapanMiddle AgedTreatment OutcomePiperazinesHIV-1Retrospective StudiesProspective StudiesAdenineAmidesDrug CombinationsPhosphinic AcidsCD4 Lymphocyte CountViral LoadCohort Studies

Substanzen

EmtricitabineTenofovirAnti-HIV AgentsAlaninebictegravirHeterocyclic Compounds, 3-RingPyridonesHeterocyclic Compounds, 4 or More RingsPiperazinesAdenine

Autor:innen und Institutionen

  • Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
  • AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • AIDS Medical Center, NHO Osaka National Hospital, Osaka, Japan.
  • Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.
  • Internal Medicine, Clinical Research Institute, NHO Kyushu Medical Center, Fukuoka, Japan.
  • Medical Affairs-HIV, Gilead Sciences K.K., Tokyo, Japan.

ORCID-Profile: Yoshiyuki Yokomaku, Takuma Shirasaka

Förderung

  • Gilead Sciences

Zitieren

APA

Yokomaku, Y., Teruya, K., Watanabe, D., Endo, T., Minami, R., Taguchi, N., Cassidy, T., Marongiu, A., Thorpe, D., Shirasaka, T., & Oka, S. (2025). Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort. PLOS ONE, 20(1), e0313338. https://doi.org/10.1371/journal.pone.0313338

Vancouver

Yokomaku Y, Teruya K, Watanabe D, Endo T, Minami R, Taguchi N, et al. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort. PLOS ONE. 2025;20(1):e0313338. doi:10.1371/journal.pone.0313338

BibTeX
@article{Yokomaku2025,
  author = {Yokomaku, Yoshiyuki and Teruya, Katsuji and Watanabe, Dai and Endo, Tomoyuki and Minami, Rumi and Taguchi, Nao and Cassidy, Tali and Marongiu, Andrea and Thorpe, David and Shirasaka, Takuma and Oka, Shinichi},
  title = {Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {1},
  pages = {e0313338},
  doi = {10.1371/journal.pone.0313338}
}
Kostenlos starten →